---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-23-000035"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T07:05:55.531935+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Caribou Q4 net loss $27M; cash $317M; CB-010 data update planned H2 2023

## Summary
- Net loss of $27.0M in Q4 2022 and $99.4M for full year 2022, vs. $18.5M and $66.9M in 2021.
- Cash, equivalents, and marketable securities $317.0M as of Dec 31, 2022; runway into 2025.
- CB-010 ANTLER trial: all 6 pts at dose level 1 achieved complete response; 6-month CR in 3/6.
- CB-011 CaMMouflage trial recruiting at dose level 1 for r/r multiple myeloma; CB-012 IND planned H2 2023.
- R&D expenses $25.7M in Q4 2022 vs. $15.1M in Q4 2021, driven by pipeline advancement and headcount.

## SEC filing metadata
- accession: 0001619856-23-000035
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000035/0001619856-23-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000035/crbu-20230309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-23-000035
- JSON: https://secwatch.observer/filing/0001619856-23-000035.json
- Plain text: https://secwatch.observer/filing/0001619856-23-000035.txt

## Key facts
- Earnings Releases
  Caribou Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.
  - Period: the fourth quarter and year ended December 31, 2022
  - Result: reported results
  source text: On March 9, 2023, Caribou Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fourth quarter and year ended December 31, 2022 and providing a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000035/0001619856-23-000035-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.